Michael Murphy (RSS)
- 2 Cancer Stocks to Approach With Caution
- Biotech Stock Zalicus Soaring in 2011
- Cancer Drug Should Take Dendreon to $360
- Zalicus Proves It’s the Best ’11 Stock
- Best Biotech Stock for 2011 – Zalicus (ZLCS)
For the last 25+ years, Michael Murphy has been an independent technology investment adviser, bringing professional research to individual investors. Through New World Investor, he shares his unique analysis of the MegaShifts -- new technology trends and breakthroughs often still flying under the radar and the companies best positioned to reap the potentially staggering rewards.Michael is a regular guest in the media with frequent appearances on CNBC and CNNfn and is often quoted in The Wall Street Journal, Barron's and Money. He graduated with honors in economics from Harvard College and began his career in the computer industry's infancy, first as COBOL programmer and mainframe systems analyst, then as the technology stock analyst for American Express in the 1970s and later as the CEO of two software companies where the lessons of this rapid-evolution world were forged in fire.